TP53 mutations in human cancers: origins, consequences, and clinical use.

Cited by (1,002)

Items 601–700 of 1,002

1. Weighted gene coexpression network analysis and machine learning reveal oncogenome associated microbiome plays an important role in tumor immunity and prognosis in pan-cancer
   Shi-Wei Guan, Quan Lin, Xidong Wu, Haibo Yu · 2023 · Journal of Translational Medicine
2. Connecting Molecular Pathways to Hereditary Cancer Risk Syndromes
   Joseph R. Testa, David M. Malkin, Joshua David Schiffman · 2013 · American Society of Clinical Oncology Educational Book
3. Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms
   E. Moore, Lillian D. Sun, Paul E. Clavijo, J. Friedman, J. Harford, Anthony D. Saleh, C. Van Waes, E. Chang, C. Allen · 2017 · Oncoimmunology
4. Switching off malignant mesothelioma: exploiting the hypoxic microenvironment
   Noushin Nabavi, Kevin L. Bennewith, Andrew Churg, Yuzhuo Z. Wang, Colin C. Collins, Luciano Mutti · 2017 · Genes & Cancer
5. Mutant p53 induces SIRT3/MnSOD axis to moderate ROS production in melanoma cells
   Margalida Torrens‐Mas, Marco Cordani, Nidula Mullappilly, Raffaella Pacchiana, Chiara Riganti, Marta Palmieri, Daniel Gabriel Pons, Pilar Roca, Jordi Oliver, Massimo Donadelli · 2019 · Archives of Biochemistry and Biophysics
6. Pathogenic genetic variants from highly connected cancer susceptibility genes confer the loss of structural stability
   Mahjerin Nasrin Reza, Nadim Ferdous, Md. Tabassum Hossain Emon, Md. Shariful Islam, A. K. M. Mohiuddin, Mohammad Uzzal Hossain · 2021 · Scientific Reports
7. Systematic review and meta‐analysis of genomic alterations in acral melanoma
   Natasa Broit, Peter A. Johansson, Chloe B. Rodgers, Sebastian Walpole, Nicholas K. Hayward, Antonia L. Pritchard · 2022 · Pigment Cell & Melanoma Research
8. Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis
   Moazzam Shahzad, Ezza Fatima Tariq, Sibgha Gull Chaudhary, Iqra Anwar, Qamar Iqbal, Huda Fatima, Haitham Abdelhakim, Nausheen Ahmed, Ramesh Balusu, Peiman Hematti et al. · 2022 · Leukemia & lymphoma/Leukemia and lymphoma
9. TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma
   Tatiana Erazo, Chiara M. Evans, Daniel Zakheim, Eren L. Chu, Alice Yunsi Refermat, Zahra Asgari, Xuejing Yang, Mariana Da Silva Ferreira, Sanjoy Mehta, Marco Vincenzo Russo et al. · 2022 · Nature Communications
10. Current insights into the regulation of programmed cell death by TP53 mutation in cancer
    Yali Su, Yingying Sai, Linfeng Zhou, Zeliang Liu, Panyan Du, Jinghua Wu, Jinghua Zhang · 2022 · Frontiers in Oncology
11. Study on the material basis and action mechanisms of sophora davidii (Franch.) skeels flower extract in the treatment of non-small cell lung cancer
    Baibai Ye, Ping Chen, Cheng Lin, Chenning Zhang, Linfu Li · 2023 · Journal of Ethnopharmacology
12. Potential role of p53 deregulation in modulating immune responses in human malignancies: A paradigm to develop immunotherapy
    Shivi Chauhan, Shivani Jaiswal, Vibhuti Jakhmola, Bhavana Pendurthi Singh, Sujata Bhattacharya, Manoj Garg, Shinjinee Sengupta · 2024 · Cancer Letters
13. Alternative mechanisms of telomere lengthening: Permissive mutations, DNA repair proteins and tumorigenic progression
    April Renee Sandy Gocha, Julia M. Harris, Joanna Louise Groden · 2012 · Mutation research. Fundamental and molecular mechanisms of mutagenesis
14. Benzo[a]pyrene induced p53-mediated cell cycle arrest, DNA repair, and apoptosis pathways in Chinese rare minnow (Gobiocypris rarus)
    Lilai Yuan, Biping Lv, Jinmiao Zha, Zijian Wang · 2016 · Environmental Toxicology
15. Emerging Roles of BRD7 in Pathophysiology
    Sang Won Park, Junsik M. Lee · 2020 · International Journal of Molecular Sciences
16. Advancements in Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Breast Cancer Therapy
    Harneet Marwah, Hitesh Kumar Dewangan · 2024 · Current Pharmaceutical Design
17. Clinical significance of DAPK promoter hypermethylation in lung cancer: a meta-analysis
    Xiaoju Zhang, Min Zhu, Dongjun Cheng, Xitao Ma, Ying Li · 2015 · Drug Design Development and Therapy
18. p53: Multiple Facets of a Rubik's Cube
    Yun Zhang, Guillermina Lozano · 2016 · Annual Review of Cancer Biology
19. Somatic hypermutation in immunity and cancer: Critical analysis of strand-biased and codon-context mutation signatures
    Edward J. Steele · 2016 · DNA repair
20. Identification of Core Biomarkers Associated with Outcome in Glioma: Evidence from Bioinformatics Analysis
    Rongxin Geng, Ning Li, Yang Xu, Junhui Liu, Fan-en Yuan, Qian Sun, Baohui Liu, Qianxue Chen · 2018 · Disease Markers
21. A quantitative model to predict pathogenicity of missense variants in the TP53 gene
    Cristina Fortuño, Arcadi Cipponi, Mandy L. Ballinger, Sean V. Tavtigian, Magali Olivier, Vatsal Ruparel, Ygal Haupt, Sue Haupt, International Sarcoma Kindred Study, Kathy Tucker et al. · 2019 · Human Mutation
22. The impact of p53 on aristolochic acid I-induced nephrotoxicity and DNA damage in vivo and in vitro
    Mateja Sborchia, Eric G. De Prez, Marie‐Hélène Antoine, Lucie Bienfait, Radek Indra, Gabriel N. Valbuena, David H. Phillips, Joëlle Nortier, Marie Stiborová, Hector C. Keun et al. · 2019 · Archives of Toxicology
23. Recent developments in detoxication techniques for aristolochic acid-containing traditional Chinese medicines
    Fan Yang, Zong‐Ming Li, Jun Xi · 2020 · RSC Advances
24. Metformin: (future) best friend of the radiation oncologist?
    Benjamin Chevalier, Dominique Pasquier, Eric Felix Lartigau, Cyrus Chargari, Antoine Schernberg, Arnaud Jannin, Xavier Mirabel, Marie‐Christine Vantyghem, Alexandre Escande · 2020 · Radiotherapy and Oncology
25. P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9
    Xiaobing Tian, Nagib Ahsan, Amriti R. Lulla, Avital Lev, Philip H. Abbosh, David T. Dicker, Shengliang Zhang, Wafik S. El‐Deiry · 2021 · Neoplasia
26. Direct evidence of cellular transformation by prion-like p53 amyloid infection
    Ambuja Navalkar, Satyaprakash Pandey, Namrata Singh, Komal Patel, Debalina Datta, Bhabani Shankar Mohanty, Sachin Hanumantrao Jadhav, Pradip R. Chaudhari, Samir Kumar Maji · 2021 · Journal of Cell Science
27. Revisiting the Role of p53 in Prostate Cancer
    Miriam Teroerde, Cathleen Nientiedt, Anette U. Duensing, Markus Hohenfellner, Albrecht Stenzinger, Stefan M. Duensing · 2021 · Exon Publications eBooks
28. Comprehensive Approach to Distinguish Patients with Solid Tumors from Healthy Controls by Combining Androgen Receptor Mutation p.H875Y with Cell-Free DNA Methylation and Circulating miRNAs
    Elena Tomeva, Olivier J. Switzeny, Clemens Heitzinger, Berit Hippe, Alexander G. Haslberger · 2022 · Cancers
29. BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms
    Naomie Devico Marciano, Gianna Kroening, Farshid Dayyani, Jason A. Zell, Fa-Chyi Lee, May Thet Cho, Jennifer Brooke Valerin · 2022 · Cancers
30. Myometrial oxidative stress drives MED12 mutations in leiomyoma
    Yi-Nuo Li, Xiu-Hua Xu, Huma Asif, Yue Feng, Brendan F. Kohrn, Scott R. Kennedy, J. Kim, Jian-Jun Wei · 2022 · Cell & Bioscience
31. Evidence for upregulated repair of oxidatively induced DNA damage in human colorectal cancer
    Güldal Kırkalı, Didem Keleş, Aras Emre Canda, Cem Terzi, Prasad T. Reddy, Paweł Jaruga, Miral Dizdaroğlu, Gülgün Oktay · 2011 · DNA repair
32. Cancer Cells Cue the p53 Response of Cancer-Associated Fibroblasts to Cisplatin
    Jens O. Schmid, Meng Dong, Silke Haubeiß, Godehard Friedel, Sabine Bode, Andreas Grabner, German Ott, Thomas E. Mürdter, Moshe Oren, Walter E. Aulitzky et al. · 2012 · Cancer Research
33. The Prevalence of Cancer-Associated Autoantibodies in Patients with Gastric Cancer and Progressive Grades of Premalignant Lesions
    Irēna Meistere, Simone Werner, Pawel Zayakin, Karīna Siliņa, Undīne Rulle, Angelina Pismennaja, Daiga Šantare, Ilze Ķikuste, Sergejs Isajevs, Mārcis Leja et al. · 2017 · Cancer Epidemiology Biomarkers & Prevention
34. Lipoic Acid Synergizes with Antineoplastic Drugs in Colorectal Cancer by Targeting p53 for Proteasomal Degradation
    Carina Neitzel, Nina Seiwert, Anja Göder, Erika Diehl, Carina Weber, Georg Nagel, Svenja Stroh, Birgit Rasenberger, Markus Christmann, Jörg Fahrer · 2019 · Cells
35. The enzyme electrocatalytic immunosensor based on functional composite nanofibers for sensitive detection of tumor suppressor protein p53
    Xiaoying Wang, Chanchan Gao, Guofang Shu, Yijie Wang, Xingang Liu · 2015 · Journal of Electroanalytical Chemistry
36. Pathophysiology and classification of pseudomyxoma peritonei
    Mark Bignell, Norman John Carr, Faheez Mohamed · 2016 · Pleura and Peritoneum
37. Torilis japonica extract-generated intracellular ROS induces apoptosis by reducing the mitochondrial membrane potential via regulation of the AMPK-p38 MAPK signaling pathway in HCT116 colon cancer
    Guen Tae Kim, Se Hee Lee, Young Min Kim · 2016 · International Journal of Oncology
38. HDAC inhibitors show differential epigenetic regulation and cell survival strategies on p53 mutant colon cancer cells
    R. Mahalakshmi, Husayn Ahmed Pallikonda, Vijayalakshmi Mahadevan · 2017 · Journal of Biomolecular Structure and Dynamics
39. Loss of Uracil DNA Glycosylase Selectively Resensitizes p53-Mutant and -Deficient Cells to 5-FdU
    Yan Yan, Yulan Qing, John J. Pink, Stanton L. Gerson · 2017 · Molecular Cancer Research
40. Multifunctional Compounds for Activation of the p53‐Y220C Mutant in Cancer
    Jessica J. Miller, Christophe Orvain, Shireen Jozi, Ryan M. Clarke, Jason R. Smith, Anaïs Blanchet, Christian Gaiddon, Jeffrey J. Warren, Tim Storr · 2018 · Chemistry - A European Journal
41. Biophysical simulations and structure-based modeling of residue interaction networks in the tumor suppressor proteins reveal functional role of cancer mutation hotspots in molecular communication
    Gennady M. Verkhivker · 2018 · Biochimica et Biophysica Acta (BBA) - General Subjects
42. Inhibition of the adenosinergic pathway: the indispensable part of oncological therapy in the future
    Yi Huang, Zili Gu, Yang Fan, Guangxi Zhai, Xiaogang Zhao, Qifeng Sun, Yanbin Shi, Guimei Lin · 2019 · Purinergic Signalling
43. Involvement of p53 Acetylation in Growth Suppression of Cutaneous T-Cell Lymphomas Induced by HDAC Inhibition
    Xiaoxuan Yu, Hui Li, Mengyuan Zhu, Po Hu, Xiao Liu, Yingjie Qing, Xiangyuan Wang, Hongzheng Wang, Zhanyu Wang, Jingyan Xu et al. · 2020 · Journal of Investigative Dermatology
44. Epigenetic Regulatory Enzymes: mutation Prevalence and Coexistence in Cancers
    Amit Sharma, Hongde Liu, Martina C. Herwig‐Carl, Tikam Chand Dakal, Ingo G.H. Schmidt‐Wolf · 2021 · Cancer Investigation
45. RETRACTED: lncRNA TRMP-S directs dual mechanisms to regulate p27-mediated cellular senescence
    Shuai Tian, Muhammad Riaz Khan, Xu Dong Zhang, Jingmin Li, Rick Francis Thorne, Mian Wu, Fengmin Shao · 2021 · Molecular Therapy — Nucleic Acids · Retracted
46. Mutant p53 Mediates Sensitivity to Cancer Treatment Agents in Oesophageal Adenocarcinoma Associated with MicroRNA and SLC7A11 Expression
    Ann-Kathrin Eichelmann, George C. Mayne, Karen Chiam, Steven L. Due, Isabell Bastian, Frederike Butz, Tingting Wang, Pamela J. Sykes, Nicholas James Clemons, David S. Liu et al. · 2021 · International Journal of Molecular Sciences
47. An African-Specific Variant of TP5 3 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
    Alexandra Indeglia, Jessica C. Leung, Sven A. Miller, Julia I-Ju Leu, James F. Dougherty, Nicole L. Clarke, Nicole A. Kirven, Chunlei Shao, Lei Ke, S. Lovell et al. · 2023 · Cancer Discovery
48. Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes
    Vivek P. Chavda, Kelsee K. Zajac, Jenna Gunn, Pankti C. Balar, Avinash D. Khadela, Dixa A. Vaghela, Shruti Soni, Charles R. Ashby, Amit Kumar Tiwari · 2023 · Cancer Reports
49. Biomarkers of oxidatively induced DNA damage in dreissenid mussels: A genotoxicity assessment tool for the Laurentian Great Lakes
    P. Jaruga, E. Coskun, K. Kimbrough, A. Jacob, W. E. Johnson, M. Dizdaroglu · 2017 · Environmental Toxicology
50. Utx loss causes myeloid transformation
    Liting Zheng, Longyong Xu, Qing Xu, Lu Yu, Danfeng Zhao, Pu Chen, Wei Wang, Yiqin Wang, Gang Han, Charlie Degui Chen · 2018 · Leukemia
51. Wasabi 6‐(methylsulfinyl)hexyl isothiocyanate induces apoptosis in human colorectal cancer cells through p53‐independent mitochondrial dysfunction pathway
    Satoshi Yano, Shusong Wu, Kozue Sakao, De‐Xing Hou · 2018 · BioFactors
52. Regulation of cisplatin resistance in lung cancer by epigenetic mechanisms
    Xiaoyan Yu, Luyu Jia, Qing Tang, Qichun Zhou, Genshu Wang, Sumei Wang · 2025 · Clinical Epigenetics
53. Differential microRNA expression in aristolochic acid-induced upper urothelial tract cancers ex vivo
    Le Tao, Yigang Zeng, Jun Wang, Zhihong Liu, Bing Shen, Jifu Ge, Yong Liu, Yifeng Guo, Jianxin Qiu · 2015 · Molecular Medicine Reports
54. Ancestry of the Brazilian TP53 c.1010G>A (p.Arg337His, R337H) Founder Mutation: Clues from Haplotyping of Short Tandem Repeats on Chromosome 17p
    Diego D’Ávila Paskulin, Juliana Giacomazzi, Maria Isabel Achatz, Sandra Costa, Rui Manuel Reis, Pierre L. Hainaut, Sidney Emanuel Batista dos Santos, Patrícia Ashton‐Prolla · 2015 · PLoS ONE
55. CircCNTNAP3-TP53-positive feedback loop suppresses malignant progression of esophageal squamous cell carcinoma
    Hui Wang, Xuming Song, Yajing Wang, Yin Xuewen, Yingkuan Liang, Te Zhang, Lin Xu, Feng Jiang, Gaochao Dong · 2020 · Cell Death and Disease
56. Molecular Genetics in Neuroblastoma Prognosis
    Margherita Lerone, Marzia Ognibene, Annalisa Pezzolo, Giuseppe Martucciello, Federico Zara, Martina Morini, Katia Mazzocco · 2021 · Children
57. A Review of Breast Cancer Risk Factors in Adolescents and Young Adults
    Una Mary McVeigh, John William Tepper, Terri Patricia McVeigh · 2021 · Cancers
58. Current Prognostic and Predictive Biomarkers for Endometrial Cancer in Clinical Practice: Recommendations/Proposal from the Italian Study Group
    Gian Franco Zannoni, Emma Bragantini, Francesca Castiglione, Matteo Fassan, Giancarlo Troncone, Frediano Socrate Inzani, Anna Pesci, Angela Santoro, Filippo Fraggetta · 2022 · Frontiers in Oncology
59. Thymoquinone Alterations of the Apoptotic Gene Expressions and Cell Cycle Arrest in Genetically Distinct Triple-Negative Breast Cancer Cells
    Getinet Mequanint Adinew, Samia S. Messeha, Equar Taka, Ramesh Babu Badisa, Lovely M. Antonie, Karam F. A. Soliman · 2022 · Nutrients
60. Alternative Lengthening of Telomeres in Cancer Confers a Vulnerability to Reactivation of p53 Function
    Shawn J. Macha, Balakrishna Koneru, Trevor A. Burrow, Charles Zhu, Dzmitry Savitski, Rakhshanda Layeequr Rahman, Catherine A. Ronaghan, Jonas Nance, Kristyn McCoy, Cody R. Eslinger et al. · 2022 · Cancer Research
61. ΔNp63 Expression is a Protective Factor of Progression in Clinical High Grade T1 Bladder Cancer
    Josep María Gaya, Juan Manuel López-Martínez, Orit Karni-Schmidt, Dennis M. Bonal, Ferran Algaba B, Joan Palou, H. Villavicencio, Mitchell C. Benson, Carlos Cordon‐Cardo, Mireia Castillo-Martín · 2014 · The Journal of Urology
62. Nuclear interactor of ARF and Mdm2 regulates multiple pathways to activate p53
    Sara M. Reed, Jussara Hagen, Van S. Tompkins, Katie Thies, Frederick W. Quelle, Dawn E. Quelle · 2014 · Cell Cycle
63. “p53 mutation spectrum and its role in prognosis of oral cancer patients: A study from Gujarat, West India”
    Ragini Singh, Kinjal R. Patel, Prabhudas Shankarbhai Patel · 2015 · Mutation research. Fundamental and molecular mechanisms of mutagenesis
64. Binding of Amphipathic Cell Penetrating Peptide p28 to Wild Type and Mutated p53 as studied by Raman, Atomic Force and Surface Plasmon Resonance spectroscopies
    Sara Signorelli, Simona Santini, Tohru Yamada, Anna Rita Bizzarri, Craig W. Beattie, Salvatore Cannistraro · 2017 · Biochimica et Biophysica Acta (BBA) - General Subjects
65. Bone and Soft-Tissue Sarcoma: A New Target for Telomerase-Specific Oncolytic Virotherapy
    Hiroshi Tazawa, Joe Hasei, Shuya Yano, Shunsuke Kagawa, Toshifumi Ozaki, Toshiyoshi Fujiwara · 2020 · Cancers
66. Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab
    Yuan, Yuan, Kos, Ferdynand J., He, Ting-Fang, Yin, Hongwei H., Li, Mengsha, Hardwick, Nicola, Zurcher, Kathryn, Schmolze, Daniel, Lee, Peter, Pillai, Raju K. et al. · 2017 · OncoImmunology
67. Dynamic changes of driver genes’ mutations across clinical stages in nine cancer types
    Xia Li · 2016 · Cancer Medicine
68. Germline mutation in the TP53 gene in uveal melanoma
    Nikola Hájková, Jan Hojny, Kristýna Němejcová, Pavel Dundr, Jan Ulrych, Kateřina Jirsová, Johana Glezgová, Ivana Tichá · 2018 · Scientific Reports
69. TP53 rs1625895 is Related to Breast Cancer Incidence and Early Death in Iranian Population
    Leila Assad Samani, Seyed-Morteza Javadirad, Soha Parsafar, Hossein Tabatabaeian, Kamran Ghaedi, Mansoureh Azadeh · 2018 · Indian Journal of Clinical Biochemistry
70. Ellagic acid, extracted from Sanguisorba officinalis, induces G1 arrest by modulating PTEN activity in B16F10 melanoma cells
    Yi Tan, Toshiyuki Shudo, Tomoki Yoshida, Yuma Sugiyama, Ying Jia, Chihiro Tsukano, Yoshiji Takemoto, Akira Kakizuka · 2019 · Genes to Cells
71. Anticancer strategies by upregulating p53 through inhibition of its ubiquitination by MDM2
    Abiodun Anifowose, Ayodeji A. Agbowuro, Xiaoxiao Yang, Binghe Wang · 2020 · Medicinal Chemistry Research
72. Context is key: Understanding the regulation, functional control, and activities of the p53 tumour suppressor
    Anne Hucks Moxley, David Reisman · 2020 · Cell Biochemistry and Function
73. Analyzing cancer gene expression data through the lens of normal tissue-specificity
    Hildreth Robert Frost · 2021 · PLoS Computational Biology
74. Redox Sensitive Cysteine Residues as Crucial Regulators of Wild-Type and Mutant p53 Isoforms
    Elena Butturini, Giovanna Butera, Raffaella Pacchiana, Alessandra Carcereri de Prati, Sofia Mariotto, Massimo Donadelli · 2021 · Cells
75. BUB3, beyond the Simple Role of Partner
    Patrícia M. A. Silva, Hassan Bousbaa · 2022 · Pharmaceutics
76. Recent advances in the application of metallomics in diagnosis and prognosis of human cancer
    Yan Zhang, Jie He, Jiao Jin, Cihan Ren · 2022 · Metallomics
77. Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations
    Jinyong Kim, Kyeonghun Jeong, Hyeji Jun, Kwangsoo Kim, Jeong Mo Bae, Myung Geun Song, Hanbaek Yi, Songyi Park, Go-un Woo, Dae‐Won Lee et al. · 2023 · Human Genomics
78. Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation
    Xiaoming Wang, Yunjin Bai, Facai Zhang, Dengxiong Li, Kai Chen, Ruicheng Wu, Yin Tang, Xin Wei, Ping Han · 2023 · Frontiers in Immunology
79. Susceptibility Genes Associated with Multiple Primary Cancers
    Mengyao Lu, Xuemei Zhang, Qian Chu, Yuan Chen, Peng Zhang · 2023 · Cancers
80. Análisis genético en APC, KRAS y TP53 en pacientes con cáncer de estómago y colon
    Katherine Andrea Palacio Rúa, L.F. Isaza-Jiménez, Enoc Ahumada Rodríguez, Hamilton Ceballos, Carlos Mario Muñetón Peña · 2014 · Revista de Gastroenterología de México
81. Jdp2 downregulates Trp53 transcription to promote leukaemogenesis in the context of Trp53 heterozygosity
    Louise van der Weyden, Alistair G. Rust, Rebecca E. McIntyre, Carla Daniela Robles‐Espinoza, Martin Del Castillo Velasco‐Herrera, Ruslan Strogantsev, Anne C. Ferguson‐Smith, Shane McCarthy, Thomas Keane, Mark Johan Arends et al. · 2012 · Oncogene
82. Ancient oncogenesis, infection and human evolution
    Riaan F. Rifkin, Marnie Potgieter, Jean‐Baptiste Ramond, Don Arthur Cowan · 2017 · Evolutionary Applications
83. The immune microenvironment in vulvar (pre)cancer: review of literature and implications for immunotherapy
    Ziena Abdulrahman, Kim E. Kortekaas, Peggy J. de Vos van Steenwijk, Sjoerd H. van der Burg, Mariette I. van Poelgeest · 2018 · Expert Opinion on Biological Therapy
84. Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma
    Fung‐Yu Huang, Danny K.-H. Wong, Vivien Wai Man Tsui, Wai‐Kay Seto, Lung‐Yi Mak, Tan To Cheung, Keane K. Y. Lai, M.-F. Yuen · 2019 · BMC Cancer
85. Mutant p53 regulates Survivin to foster lung metastasis
    Qiaosi Tang, Gizem Efe, Anna M. Chiarella, Jessica C. Leung, Maoting Chen, Taiji Yamazoe, Zhenyi Su, Jason Robert Pitarresi, Jinyang Li, Mirazul Islam et al. · 2021 · Genes & Development
86. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation
    Britt, Alec, Mohyuddin, Ghulam Rehman, McClune, Brian, Singh, Anurag, Lin, Tara, Ganguly, Siddhartha, Abhyankar, Sunil, Shune, Leyla, McGuirk, Joseph, Skikne, Barry et al. · 2020 · Leukemia Research
87. Targeting the JAK2–STAT3–UCHL3–ENO1 axis suppresses glycolysis and enhances the sensitivity to 5-FU chemotherapy in TP53-mutant colorectal cancer
    Haisong Xin, Zitong Zhao, Shichao Guo, Ruoxi Tian, Liying Ma, Yang Yang, Lianmei Zhao, Guanglin Wang, Baokun Li, Xuhua Hu et al. · 2025 · Acta Pharmaceutica Sinica B
88. CXCL12 and TP53 genetic polymorphisms as markers of susceptibility in a Brazilian children population with acute lymphoblastic leukemia (ALL)
    Aparecida de Lourdes Perim, Roberta Losi Guembarovski, Julie Massayo Maeda Oda, Leandra Fiori Lopes, Carolina Batista Ariza, Marla Karine Amarante, Maria Helena Pelegrinelli Fungaro, Karen Brajão de Oliveira, Maria Angélica Ehara Watanabe · 2013 · Molecular Biology Reports
89. Acquired somatic TP53 or PIK3CA mutations are potential predictors of when polyps evolve into colorectal cancer
    Pi-Yueh Chang, Jinn‐Shiun Chen, Shih‐Cheng Chang, Mei-Chia Wang, Nai-Chung Chang, Ying-Hao Wen, Wen‐Sy Tsai, Wei‐Hsiu Liu, Hsiu-Ling Liu, Jang‐Jih Lu · 2017 · Oncotarget
90. Unprovoked Stabilization and Nuclear Accumulation of the Naked Mole-Rat p53 Protein
    Marian M. Deuker, Kaitlyn N. Lewis, Maria Ingaramo, Jacob C. Kimmel, Rochelle Buffenstein, Jeff Settleman · 2020 · Scientific Reports
91. Chromosome Region Maintenance 1 (XPO1/CRM1) as an Anticancer Target and Discovery of Its Inhibitor
    Song Liu, Wenliang Qiao, Qingxiang Sun, Youfu Luo · 2021 · Journal of Medicinal Chemistry
92. Genomic profiling of gallbladder carcinoma: Targetable mutations and pathways involved
    Sridhar Mishra, Swati Kumari, Pallavi Srivastava, Anshuman Pandey, Saumya Shukla, Nuzhat Husain · 2022 · Pathology - Research and Practice
93. P63 and P73 Activation in Cancers with p53 Mutation
    Bi‐He Cai, Yun-Chien Hsu, Fang-Yu Yeh, Yu-Rou Lin, Rui-Yu Lu, Si-Jie Yu, Jei‐Fu Shaw, Ming-Han Wu, Yi-Zhen Tsai, Ying-Chen Lin et al. · 2022 · Biomedicines
94. Anticancer Therapeutic Strategies Targeting p53 Aggregation
    Giulia D. S. Ferretti, Julia Quarti, Gileno dos Santos, Luciana Pereira Rangel, Jerson Lima Silva · 2022 · International Journal of Molecular Sciences
95. Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells
    Michelle Bhatt, Cristina Ivan, Xiaolei Xie, Zahid Hussain Siddik · 2016 · Oncotarget
96. The mutational status of p53 can influence its recognition by human T-cells
    Katerina Shamalov, Shlomo N. Levy, Miryam Horovitz‐Fried, Cyrille J. Cohen · 2017 · OncoImmunology
97. Molecular Regulation of Cellular Senescence by MicroRNAs: Implications in Cancer and Age-Related Diseases
    Mathieu Neault, Florence Couteau, Éric Bonneau, Vincent De Guire, Frédérick A. Mallette · 2017 · International review of cytology
98. The p53/Adipose-Tissue/Cancer Nexus
    Kevin J. Zwezdaryk, Deborah E. Sullivan, Zubaida R. Saifudeen · 2018 · Frontiers in Endocrinology
99. Dynamic perspectives into the mechanisms of mutation‐induced p53‐DNA binding loss and inactivation using active perturbation theory: Structural and molecular insights toward the design of potent reactivators in cancer therapy
    Fisayo Andrew Olotu, Mahmoud E. S. Soliman · 2018 · Journal of Cellular Biochemistry
100. Integrated Clinico-Molecular Characterization Identifies RAS Activation and CDKN2A Deletion As Independent Adverse Prognostic Factors in Cancer of Unknown Primary
     Tilmann Bochtler, Anna Reiling, Volker Endris, Thomas Hielscher, Anna‐Lena Volckmar, Olaf Neumann, Martina Kirchner, Jan Budczies, Lukas Carl Heukamp, Jonas Leichsenring et al. · 2019 · International Journal of Cancer